title: Factors influencing linezolid-nonsusceptible coagulase-negative staphylococci dissemination among patients in the intensive care unit: a retrospective cohort study.
abstract: BACKGROUND
  The aim of the present study was to identify risk factors for linezolid-nonsusceptible coagulase-negative staphylococci (CNS) dissemination in the intensive care unit.
  
  
  METHODS
  Among the 246 patients included, 33 revealed a linezolid-nonsusceptible CNS-positive culture specimen, 68 were positive for linezolid-susceptible CNS and 145 served as controls. Isolates were characterized by phenotypic and genotypic methods to species level, susceptibility to antistaphylococcal agents and clones.
  
  
  RESULTS
  Among the 33 linezolid-nonsusceptible CNS patients, 29 revealed Staphylococcus epidermidis and 4 Staphylococcus capitis. All S. epidermidis strains belonged to the ST22 clone (by multilocus sequence typing), 26 carried both C2534T and T2504A and 3 strains were C2543T mutations. S. capitis strains were stratified as a common pulsed-field gel electrophoresis type and carried the G2576T mutation. Risk factors for linezolid-nonsusceptible CNS isolation were linezolid administration and mean number of linezolid-nonsusceptible CNS-positive patients in nearby beds per day.
  
  
  CONCLUSIONS
  These results reinforce the aspect of rational antibiotic usage, but also highlight the need for strict infection control measures to prevent the dissemination of linezolid-nonsusceptible CNS.
authors: Division of Infectious Diseases, School of Medicine, University of Patras, Patras, Greece.
authors: Matthaios
authors: M
authors: Papadimitriou-Olivgeris
authors: Nikolaos
authors: N
authors: Giormezis
authors: Fotini
authors: F
authors: Fligou
authors: Apostolos
authors: A
authors: Liakopoulos
authors: Markos
authors: M
authors: Marangos
authors: Evangelos D
authors: ED
authors: Anastassiou
authors: Efthimia
authors: E
authors: Petinaki
authors: Kriton S
authors: KS
authors: Filos
authors: Iris
authors: I
authors: Spiliopoulou
mesh_terms: D000081:Acetamides / Q000494:pharmacology* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D003030:Coagulase / Q000235:genetics / Q000378:metabolism*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007362:Intensive Care Units; D000069349:Linezolid; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009154:Mutation; D023303:Oxazolidinones / Q000494:pharmacology* / Q000627:therapeutic use; D010641:Phenotype; D012338:RNA, Ribosomal, 23S / Q000235:genetics; D012189:Retrospective Studies; D012307:Risk Factors; D013203:Staphylococcal Infections / Q000188:drug therapy; D013210:Staphylococcus / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D003030:Coagulase; D023303:Oxazolidinones; D012338:RNA, Ribosomal, 23S; D000069349:Linezolid